clinical trial · NCT06719128
A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants
Eli Lilly and Company·phase1·completed·n = 46
Hepatic InsufficiencyHealthyOlomorasib
brief summary
The main purpose of this study is to assess how olomorasib gets into the blood stream and how long it takes the body to remove it when administered to participants with mild, moderate and severe impaired liver function compared to participants with normal liver function. The safety and tolerability of olomorasib will also be evaluated. The study may last up to 6 weeks for each participant including the screening period.
started
Dec 6, 2024
primary completion
Aug 25, 2025
completion
Aug 25, 2025
last updated
Sep 22, 2025
official title
An Open-Label, Nonrandomized, Single-Dose, Safety and Pharmacokinetic Study of LY3537982 in Participants With Hepatic Impairment and Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol